Picture of PAVmed logo

PAVM — PAVmed News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

PAVmed Inc expected to post a loss of $1.89 a share - Earnings Preview

* PAVmed Inc  PAVM.OQ   PAVM.O  is expected to show a rise
in
quarterly revenue when it reports  results on March 25 for the
period ending December 31 2023
    * The New York City-based  company is expected to report a
835.7% increase in revenue to $1.048 million from $112 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for PAVmed Inc is for a loss
of
$1.89 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PAVmed Inc
is
$15.00​, above​ its last closing price of $2.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -2.04       -2.05      -2.40     Missed  -17.1
 Jun. 30 2023  -2.84       -2.85      -2.10     Beat    26.3
 Mar. 31 2023  -3.11       -3.10      -2.85     Beat    8.1​
 Dec. 31 2022  -3.84       -3.80      -3.45     Beat    9.2
 ​​Sep.        -3.98       -3.97      -4.35     Missed  -9.4
 30 2022                                                
 Jun. 30 2022  -3.45       -3.45      -4.35     Missed  -26.1​
 Mar. 31 2022  -2.88       -2.92      -3.00     Missed  -2.6
 Dec. 31 2021  -2.10       -2.25      -3.00     Missed  -33.3
 This summary was machine generated March 22 at 20:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on PAVmed

See all news